Paclitaxel and Carboplatin for Metastatic Urothelial Cancer
Author Information
Author(s): CC Zielinski, B Schnack, M Grbovic, T Brodowicz, C Wiltschke, G Steger, H PflOger, M Marberger
Primary Institution: University Hospital, Vienna, Austria
Hypothesis
The study aims to assess the efficacy and toxicity of a combination of paclitaxel and carboplatin as first-line chemotherapy in patients with metastatic transitional cell carcinoma of the urothelium.
Conclusion
The combination of paclitaxel and carboplatin is an effective and well-tolerated first-line treatment for metastatic urothelial cancer.
Supporting Evidence
- 65% of patients achieved remissions, with 40% achieving complete remission.
- 80% of patients were alive after a mean observation period of 11.4 months.
- The mean duration of responses was 8.5 months.
Takeaway
This study tested a new medicine for patients with a type of bladder cancer, and it helped many of them feel better without making them too sick.
Methodology
Patients received paclitaxel and carboplatin every 21 days, and their responses were monitored over a mean observation period of 11.4 months.
Limitations
The study had a small sample size and was limited to patients with specific inclusion criteria.
Participant Demographics
The study included 20 patients (12 women, 8 men) with a mean age of 67 years, ranging from 50 to 79 years.
Want to read the original?
Access the complete publication on the publisher's website